Avonex (Interferon Beta-1A) - Summary

AVONEX SUMMARY

AVONEX is a 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons.

AVONEX (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

See all Avonex indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Avonex (Interferon Beta-1A)

Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. [2014]
function in MS... CONCLUSIONS: Different types of DMTs may improve some aspects of cognitive

Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. [2013]
The appearance of neutralizing antibodies (NAbs) has significant clinical and regulatory consequences for interferons in patients with multiple sclerosis (MS). In a double blind, randomized clinical trial, 84 patients with relapsing remitting MS were enrolled in a 24month study period... As similar results were obtained from CinnoVex or Avonex in our study, we suggest that both medications will have a similar immunogenetic profile.

Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial. [2012]
USA) and CinnoVex (CinnaGen, Iran)... CONCLUSION: CinnoVex can be used as a safe and effective alternative to Avonex in

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. [2012]
combined with low-dose azathioprine and prednisone in multiple sclerosis... CONCLUSION: The tested combined therapeutic regimen does not improve long-term

Interferon beta for secondary progressive multiple sclerosis. [2012]
CONCLUSIONS: Well designed RCTs, evaluating a high number of patients

more studies >>

Clinical Trials Related to Avonex (Interferon Beta-1A)

Immunogenicity and Safety Study of Serum-Free Avonex [Completed]
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.

A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers [Completed]

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe [Completed]
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.

Evaluate the Safe and Effective Use of the Avonex� Single-Use Autoinjector in Multiple Sclerosis Subjects [Completed]
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) [Completed]
The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging (MRI) lesions in Chinese patients with clinically diagnosed (using revised McDonald criteria) relapsing multiple sclerosis (MS).

more trials >>

Reports of Suspected Avonex (Interferon Beta-1A) Side Effects

Influenza Like Illness (821),  Multiple Sclerosis Relapse (734),  Fall (726),  Gait Disturbance (517),  Fatigue (437),  Pain (399),  Headache (357),  Memory Impairment (355),  Injection Site Pain (335),  Injection Site Haemorrhage (316), more >>